RBC Capital analyst Luca Issi maintained a Buy rating on Verve Therapeutics (VERV – Research Report) on November 7 and set a price target of $35.00. The company’s shares closed yesterday at $16.75.
Issi covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, BioMarin Pharmaceutical, and Ionis Pharmaceuticals. According to TipRanks, Issi has an average return of -29.6% and a 15.79% success rate on recommended stocks.
Currently, the analyst consensus on Verve Therapeutics is a Moderate Buy with an average price target of $39.75, implying a 137.31% upside from current levels. In a report released on November 7, BMO Capital also reiterated a Buy rating on the stock with a $56.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Based on Verve Therapeutics’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $53.98 million. In comparison, last year the company had a GAAP net loss of $40.95 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Verve Therapeutics (VERV) Company Description:
Verve Therapeutics Inc is a genetic medicines company pioneering the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. Its initial programs focus on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. The company is developing these gene-editing treatments for patients with familial hypercholesterolemia, a genetic disease that causes life-long severely elevated blood cholesterol.
Read More on VERV:
- Verve Therapeutics (NASDAQ:VERV) Vaults Upward on Third Quarter Results
- Verve Therapeutics Highlights Recent Company Progress and Reports Third Quarter 2023 Financial Results
- Verve Therapeutics reports Q3 EPS (72c), consensus (92c)
- Verve Therapeutics, Eli Lilly expand relationship
- Verve and Lilly Relationship Expands to Include Verve’s In Vivo Gene Editing Programs Targeting PCSK9 and ANGPTL3
